Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up.


Journal

Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579

Informations de publication

Date de publication:
2021
Historique:
received: 25 10 2021
accepted: 25 11 2021
entrez: 3 1 2022
pubmed: 4 1 2022
medline: 8 1 2022
Statut: epublish

Résumé

As of November 17, 2021, SARS-CoV-2 (Severe Acute Respiratory Syndrome CoronaVirus 2), the causative agent of COVID-19 (COronaVIrus Disease 19), has infected ~250 million people worldwide, causing around five million deaths. Titers of anti-SARS-CoV-2 neutralizing antibodies were relatively stable for at least 9 months in a population-based study conducted in Wuhan, China, both in symptomatic and in asymptomatic individuals. In the mass screening campaign conducted in the town of Ariano Irpino (Avellino, Italy) in May, 2020, 5.7% (95% CI: 5.3-6-1) of the 13,444 asymptomatic citizens screened were positive for anti-nucleocapsid antibodies against SARS-CoV-2. Among these, 422 citizens were re-tested for anti SARS-CoV-2 antibodies in January, 2021 and/or in April, 2021 and enrolled in this longitudinal observational study. Median (interquartile range) age of the study cohort was 46 years (29-59), with 47 (11.1%) participants of minor age, while 217 (51.4%) participants were females. There was no evidence of re-infection in any of the subjects included. Presence of anti-nuclear antibodies antibodies (Elecysis, Roche) was reported in 95.7 and 93.7% of evaluable participants in January and April, 2021. Multiple logistic regression analysis used to explore associations between age, sex and seroprevalence showed that adults vs. minors had significantly lower odds of having anti-S1 antibodies (Biorad) both in January, 2021 and in April, 2021. Our findings showed that antibodies remained detectable at least 11.5 months after infection in >90% of never symptomatic cases. Further investigation is required to establish duration of immunity against SARS-CoV-2.

Identifiants

pubmed: 34976939
doi: 10.3389/fpubh.2021.801609
pmc: PMC8718636
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

801609

Informations de copyright

Copyright © 2021 Coppola, Buonerba, Cardinale, Lo Conte, Sansone, Rofrano, De Vita, Morgante, Triassi, Atripaldi, Brambilla, Sabatino, Pierri, Pacella, Pizzolante, Pierri, Ferrucci, Zollo, Capasso, Stringhini, Ascierto, Roperto and Cerino.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Lancet Infect Dis. 2021 Jan;21(1):52-58
pubmed: 33058797
FEBS Lett. 2006 Oct 16;580(24):5612-20
pubmed: 16989815
Lancet Infect Dis. 2020 Dec;20(12):1390-1400
pubmed: 32979318
Emerg Microbes Infect. 2021 Dec;10(1):774-781
pubmed: 33830901
Lancet. 2021 Mar 20;397(10279):1075-1084
pubmed: 33743869
Future Sci OA. 2021 Jan 12;7(4):FSO673
pubmed: 33815819
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Int J Infect Dis. 2020 Dec;101:314-322
pubmed: 33045429
J Infect Dis. 2021 Feb 3;223(2):197-205
pubmed: 33535236
Microbiol Spectr. 2021 Sep 3;9(1):e0034121
pubmed: 34346750
J Virol. 2006 Jan;80(2):941-50
pubmed: 16378996
Clin Chem Lab Med. 2020 Oct 25;58(11):e251-e253
pubmed: 32692698
Med (N Y). 2021 Mar 12;2(3):313-320.e4
pubmed: 33554155
Lancet. 2020 Nov 14;396(10262):1595-1606
pubmed: 33065034
Int J Surg. 2014 Dec;12(12):1495-9
pubmed: 25046131
BMC Infect Dis. 2021 Aug 30;21(1):889
pubmed: 34461847
Clin Infect Dis. 2021 Nov 2;73(9):e2946-e2951
pubmed: 32840608
Clin Biochem. 2021 Nov;97:54-61
pubmed: 34453893

Auteurs

Annachiara Coppola (A)

Centro di Referenza Nazionale per l'Analisi e Studio di Correlazione tra Ambiente, Animale e Uomo, Istituto Zooprofilattico Sperimentale del Mezzogiorno, Portici, Italy.
Dipartimento di Medicina Sperimentale, Universita' degli studi della Campania "L. Vanvitelli", Naples, Italy.

Carlo Buonerba (C)

Centro di Referenza Nazionale per l'Analisi e Studio di Correlazione tra Ambiente, Animale e Uomo, Istituto Zooprofilattico Sperimentale del Mezzogiorno, Portici, Italy.

Davide Cardinale (D)

Centro di Referenza Nazionale per l'Analisi e Studio di Correlazione tra Ambiente, Animale e Uomo, Istituto Zooprofilattico Sperimentale del Mezzogiorno, Portici, Italy.

Gabriella Lo Conte (G)

Centro di Referenza Nazionale per l'Analisi e Studio di Correlazione tra Ambiente, Animale e Uomo, Istituto Zooprofilattico Sperimentale del Mezzogiorno, Portici, Italy.

Donato Sansone (D)

Centro di Referenza Nazionale per l'Analisi e Studio di Correlazione tra Ambiente, Animale e Uomo, Istituto Zooprofilattico Sperimentale del Mezzogiorno, Portici, Italy.

Giuseppe Rofrano (G)

Centro di Referenza Nazionale per l'Analisi e Studio di Correlazione tra Ambiente, Animale e Uomo, Istituto Zooprofilattico Sperimentale del Mezzogiorno, Portici, Italy.

Sabato De Vita (S)

Centro di Referenza Nazionale per l'Analisi e Studio di Correlazione tra Ambiente, Animale e Uomo, Istituto Zooprofilattico Sperimentale del Mezzogiorno, Portici, Italy.

Maria Morgante (M)

Azienda Sanitaria Locale Avellino, Avellino, Italy.

Maria Triassi (M)

Department of Public Health, Federico II University of Naples, Naples, Italy.

Luigi Atripaldi (L)

Cotugno Hospital, AORN Ospedali dei Colli, Naples, Italy.

Gianfranco Brambilla (G)

Istituto Superiore di Sanità, Food Safety, Nutrition, and Veterinary Public Health Department, Rome, Italy.

Rocco Sabatino (R)

Centro di Referenza Nazionale per l'Analisi e Studio di Correlazione tra Ambiente, Animale e Uomo, Istituto Zooprofilattico Sperimentale del Mezzogiorno, Portici, Italy.
Cotugno Hospital, AORN Ospedali dei Colli, Naples, Italy.

Andrea Pierri (A)

Centro di Referenza Nazionale per l'Analisi e Studio di Correlazione tra Ambiente, Animale e Uomo, Istituto Zooprofilattico Sperimentale del Mezzogiorno, Portici, Italy.

Daniela Pacella (D)

Department of Public Health, Federico II University of Naples, Naples, Italy.

Antonio Pizzolante (A)

Centro di Referenza Nazionale per l'Analisi e Studio di Correlazione tra Ambiente, Animale e Uomo, Istituto Zooprofilattico Sperimentale del Mezzogiorno, Portici, Italy.

Biancamaria Pierri (B)

Centro di Referenza Nazionale per l'Analisi e Studio di Correlazione tra Ambiente, Animale e Uomo, Istituto Zooprofilattico Sperimentale del Mezzogiorno, Portici, Italy.

Veronica Ferrucci (V)

CEINGE Biotecnologie Avanzate, Naples, Italy.

Massimo Zollo (M)

CEINGE Biotecnologie Avanzate, Naples, Italy.

Mario Capasso (M)

CEINGE Biotecnologie Avanzate, Naples, Italy.

Silvia Stringhini (S)

Division and Department of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.

Paolo Antonio Ascierto (PA)

Unit of Melanoma, Cancer Immunotherapy & Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.

Sante Roperto (S)

Dipartimento di Medicina Veterinaria e Produzioni Animali, Università di Napoli Federico II, Naples, Italy.

Pellegrino Cerino (P)

Centro di Referenza Nazionale per l'Analisi e Studio di Correlazione tra Ambiente, Animale e Uomo, Istituto Zooprofilattico Sperimentale del Mezzogiorno, Portici, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH